Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

The Broad Institute, Inc.

Naomi Barak

Andrea Rotgeri

Ulrich Bothe

Tobias Marquardt

Oliver Martin Fischer

Matthias Busemann

Antonius Ter Laak

Roman Hillig

Roland Neuhaus

Thomas Brumby

Ingo Hartung

Steven James Ferrara

Clara Christ

Detlef Stöckigt

Christian Stegmann

Stefan Nikolaus Gradl

Timo Stellfeld

Simon Anthony Herbert

Daniel Korr

Vera Pütter

Andreas Sutter

Matyas Gorjanacz

Volker Badock

Jeffrey Stuart Mowat

Silke Köhr

Jörg Weiske

Carlo Stresemann

Ernesto Amaury Fernandez-Montalvan

Jacob Jaffe

Craig Strathdee

Stefan Niklaus Gradl

Léa Aurelie Bouché

Isabella Gashaw

Ian Stefanuti

Rosemary Helen Crampton

Amaury Ernesto Fernandez-montalvan

Jörg Wichard

Robin Meier

Léa Bouche

Emesto Amaury Fernandez-Montalvan

Jacob D Jaffe

The present invention provides acyl sulfonamide compounds of general formula (I):

Acyl sulfonamides for treating cancer

The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R, R, R, R, R, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility. 

Aryl-cyanoguanidine compounds

The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis. 

Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)

The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.

3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments

Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments

Growing community of inventors

Berlin, Germany

Naomi Barak